Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Salivary Gland Neoplasms 1Bulbo-Spinal Atrophy, X-Linked 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Cisplatin 4Paclitaxel 3Docetaxel 3Taxes 2Radiotherapy, Conformal 2Polymerase Chain Reaction 2Immunohistochemistry 2Gene Expression Profiling 2Gemcitabine 2Carboplatin 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1mercaptoundecahydrododecaborate 1bicalutamide 1Vorinostat 1Triptorelin Pamoate 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Pilocarpine 1Methotrexate 1Irinotecan 1In Situ Hybridization 1Erlotinib Hydrochloride 1Doxorubicin 1Chemotherapy, Adjuvant 1CP protocol 1Biopsy 1Amplified Fragment Length Polymorphism Analysis 14-boronophenylalanine-fructose 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Salivary Gland Neoplasms × CP protocol × Clear all
NCT01969578 2024-11-05

Androgen Deprivation Therapy in Advanced Salivary Gland Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
149 enrolled
Head & Neck

Adenocarcinoma, Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon âš¡